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INTRODUCTION AND REVIEW OF LITERATURE   
Disturbances of the natural balance between the procoagulant and anticoagulant systems of the 
hemostasis - due to genetic or acquired factors - may result in bleeding or thrombotic diseases. 
Diseases that affect veins and/or arteries manifest as venous thromboembolism or pulmonary 
embolism are the leading causes of death worldwide. The enhanced activation of the hemostatic 
system can be caused by greater or longer than the physiologic activation of the cells in the 
circulation. The mediators that are secreted by the cells can also lead to enhanced activation of 
the hemostatic system.  
Platelets have an essential role in the activation of the hemostatic system and the aberrant 
activation of platelets play a crucial role in the pathogenesis of atherosclerotic diseases. The 
events are triggered by disruption of the endothelium, plaque rupture or during interventions on 
coronaries, when platelets tether to surface-bound von Willebrand Factor (vWF), which 
initiates platelet activation and allows them to adhere to subendothelial components.  
The aim of this study was to explore the effects of the phosphatase inhibitor calyculin A (CLA) 
on resting and activated platelets and to simultaneously investigate clot formation, platelet 
activation, and thrombin generation and their modulation in platelet rich plasma. 
Phosphatidylserine (PS)-expression, intracellular calcium responses using a novel cytosolic 
Ca2+ level measurement, clot retraction and thrombin generation were studied with or without 
TRAP activation. 
It is known that malignant diseases can be associated with an increased risk of venous 
thromboembolism compared to the healthy population. This can be associated with solid tumors 
and hematological malignancies. Numerous factors may be involved in the development of 
thromboembolic events i) activation of the malignant cells, ii) the procoagulant proteins that 
are expressed on the cell surface or the shedding of procoagulant microparticles and iii) the 
production of interleukins, cytokines and other mediators. One type of acute myeloblastic 
leukemia (AML), the acute promyelocytic leukemia has long been described to cause activation 
of blood coagulation and thus can lead to disseminated intravascular coagulation, however, 
other AML types are lot less investigated in this respect. Aside from these well documented 
causes, acute leukemias can develop a hypercoagulable state, that frequently remains 
subclinical. 
We hypothesized that monocytic leukemic cells have a higher procoagulant activity, thus we 
characterized their thrombin generating potential by different assays using coagulation factor 
deficient plasmas and TF neutralization. Results were compared to isolated normal human 
monocytes as negative- and to an acute promyelocytic leukemia cell line as positive controls. 
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The activation of the coagulation cascade in atherothrombotic status, the 
role of platelets 
Platelets play a crucial role in physiologic hemostasis as well as in pathological conditions, 
platelets are important contributors of cardiovascular diseases underlying atherosclerosis. 
Pathological events are triggered by disruption of the endothelium, plaque rupture, when 
proteins of the subendothelial matrix (collagen, fibronectin, laminin) exposed, including the 
surface-bound von Willebrand Factor (vWF), which initiates platelet activation and allows 
them to adhere to subendothelial components. After adhesion platelets become activated, a 
shape change occurs subsequently procoagulant proteins are secreted from their intracellular 
granules and aggregation is triggered.  
 
Ways of platelet activation 
Different mediators can lead to platelet activation. Adenosine-diphosphate (ADP) activates 
platelets through their membrane P2Y12 receptor. Thromboxane-A2 has an important role in the 
formation of primer thrombocyte plug through the platelet thromboxane-A2 receptors. Collagen 
activates the glycoprotein Ib (GPIb), glycoprotein IIb/IIIa (GPIIb/IIIa), glycoprotein Ia/IIa 
(GPIa/IIa) and glycoprotein VI (GPVI) receptors and provide thrombocyte-vWF to platelet-
homotypic interactions. Protease-activated receptor 1 (PAR-1), the primary platelet thrombin 
receptor is G-protein-coupled. The activation of this receptor is the strongest platelet agonist 
and an important contributor to atherothrombotic processes. PAR-1 receptor activation via 
thrombin or relevant thrombin receptor activating peptides (TRAPs) results in a series of 
signaling events terminating in platelet shape change and granule secretion via the G12/13 
proteins and intracellular calcium release via the Gq mediated inositol triphosphate (IP3) 
pathway. Intracellular IP3 receptors can be directly activated by pharmacological agents like 
thiomersal that has been used previously as a calcium mobilizer and cell function-modulating 
agent. 
Activation of platelets is associated with the exposure of negatively charged phospholipids, 
which have high potential to bind coagulation factors and assemble enzyme-cofactor complexes 
that are crucially important for efficient propagation of the system. Under normal conditions, 
PS is present in the inner-layer leaflet of the plasma cell membrane.  
 
 
   
 5 
Venous thromboembolic complications in malignancies 
The clinical manifestations of hemostasis deregulation may vary from a subclinical 
asymptomatic hypercoagulable state to manifest thrombosis of the large vessels or, further, to 
systemic disseminated intravascular coagulation with severe bleeding. The risk of venous 
thromboembolism (VTE) in malignant cancer patient is 7-fold higher compared to the healthy 
population. Multiple clinical risk factors including the classical thrombosis risk factors (i.e. 
immobility, age, surgery-related) and the tumor specific factors (type of cancer, stage of cancer, 
chemotherapy) influence the risk of VTE. According to novel results, procoagulant factors (i.e. 
tissue factor) expressed on the surface of tumor tissue can activate the hemostatic system or 
other cells of the host. Microparticles, inflammatory cytokines (e.g. TNFa, IL-1b) shed from 
the intracellular granules, adhesion molecules and proangiogenic factors produced by the 
malignant cell or activated cell can contribute to the procoagulant effect. Platelets can be 
activated directly by the tumor cells or indirectly by agonist secreted by the tumor cells in the 
circulation. During activation, the platelet surface becomes procoagulant and promotes the the 
function of the coagulation cascade, while shedding of microparticles propagate the 
procoagulant effect.  
Venous thromboembolic complication in malignant hematological diseases 
In malignant hematological diseases, including acute leukemias the risk of VTE was considered 
low and rather bleeding complications were expected. Recent studies show that VTE risk in 
hematological malignancies is similar to that established in solid tumors. Numerous factors may 
be involved in the development of thromboembolic events in leukemias. Several of these cases 
may be related to therapeutic interventions like the central venous catheter associated 
prothrombotic effect or the therapy-associated thrombotic events of L-asparaginase treatment. 
One type of the acute myeloblastic leukemias (AML), the acute promyelocytic leukemia has 
long been described to cause activation of blood coagulation and thus can lead to disseminated 
intravascular coagulation. Other AML and ALL types are lot less investigated in this respect, 
although systemic coagulation activation has been detected in other types of AML and ALL as 
well. 
 
The origin of microparticles and their procoagulant role 
Microparticles (MP) range in size from 0.1-1.0 µm in diameter, formed from membrane blebs 
that are released from the cell surface by proteolytic cleavage of the cytoskeleton of apoptotic 
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or activated cells. Microparticles are present in the blood of healthy individuals and are 
increased in various diseases, including cardiovascular disease, diabetes, sepsis and cancer. In 
peripheral blood the number of the microparticles derived from platelets is the highest (80%), 
but microparticles derived from granulocytes, endothelial cells, red blood cells or monocyte 
can also found in the circulation. During the formation of MPs there is loss of membrane 
asymmetry with ionic phospholipids being transferred to the outer membrane of the MP.  
Importantly, the presence of PS significantly increases the procoagulant activity of MPs 
because it facilitates the assembly of components of the clotting cascade.  
 
Thrombin generation test and its application 
Thrombin is the key enzyme plays a pivotal role in clot promotion, it has numerous essential 
biological function, like the activation of thrombocytes, catalyzes the conversion of fibrinogen 
to fibrin and provides a positive feedback for the coagulation cascade.  The formation of 
thrombin is one of the most important step of the coagulation process.  
Conversion of fibrinogen to fibrin and formation of clot occurs when less than 5% of the total 
thrombin has been generated. Clot formation is the endpoint in standard clot-based assays, such 
as the prothrombin time (PT) and activated partial thromboplastin time (APTT), indicating that 
the PT and the APTT are determined by less than 5% of the thrombin generated in a sample. It 
means that most of the thrombin (>95%) is generated after the moment of clotting, therefore 
the clotting time is not automatically a relevant indicator of thrombin activity.  
Thrombin generation test (TGT) is a global hemostasis test measures the amount and kinetic of 
generated thrombin in a time course. Originally the TGT was expanded for platelet poor plasma 
(PPP) examination. It is suitable for the measurement of platelet rich plasma and whole blood 
also. The ex vivo generated thrombin can be measured after the addition of a small amount of 
activator (trigger reagent) to the sample.  
In our experiments the thrombin generation test was performed under modified conditions, as 
we were interested in cell-induced thrombin formation. The thrombin generation was measured 
in platelet rich plasma after activation and/or inhibition of platelets by adding 1 pM recombinant 
TF. In this model the phospholipid expressed on the surface of platelets provided the 
propagation in the model. 
In the leukemia cell and leukemic MP studies we did not use any trigger reagent, the 
procoagulant proteins on the surface of the cells or microparticles provided the trigger for 
thrombin generation initiation and propagation.  
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OBJECTIVES 
 
1. Effect of calyculin-A on platelet activation 
Our aim was to explore the effects of the protein phosphatase inhibitor CLA on clot 
formation, platelet activation, and thrombin generation in platelet rich plasma. We 
hypothesized that CLA inhibits platelet activation the subsequent thrombin generation 
and influence clot structure. As a common mechanism, we postulated that CLA 
influences intracellular calcium levels. 
 
2. The determination of procoagulant potential of acute monocytic leukemia 
cell lines  
In our experiments we examined the procoagulant potential of three acute monocytic 
leukemia cell lines. Our hypothesis was, that the monocytic leukemia cell lines have a 
higher procoagulant potential compared to isolated normal human monocytes. 
 
3. Examination of cellular models with thrombin generation test 
Our aim was to examine thrombin generation after modulating platelet function in 
platelet rich plasma and to set up a model to determine the procoagulant potential of 
monocytes or monocytic leukemia cells. 
  
 
 
MATERIALS AND METHODS 
 
Preparation of platelet poor plasma  
For each experiments, peripheral blood was drawn from 5 healthy volunteers - with no 
medications for at least 2 weeks prior to the experiments - in vacutainer tubes containing 0.105 
M sodium citrate (Becton Dickinson, Franklin Lakes, NJ). Platelet poor plasma was separated 
by centrifugation at 1220 g for 15 min, room temperature according to the protocol that used in 
our routine diagnostic laboratory. Pooled platelet rich plasma was prepared by adding 1-1 mL 
of platelet poor plasma of each individuals. Platelet poor plasma is called hereafter normal 
plasma. 
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Preparation of platelet rich plasma  
Whole blood was drawn from healthy volunteers with no medications for at least 2 weeks prior 
to the experiments. Blood samples from volunteers was drawn in vacutainer tubes containing 
0.105 M sodium citrate (Becton Dickinson, Franklin Lakes, NJ). Platelet rich plasma (PRP) 
was prepared from venous whole blood by centrifugation at 170 x g for 15 minutes at room 
temperature (RT). Platelet count of PRP was adjusted to 250 G/L by adding platelet poor plasma 
(PPP). PPP was obtained by centrifugation of the citrated blood sample at 1500 x g for 15 
minutes at RT. In subsequent experiments the following PRP samples were analysed:  
1. Non-activated sample (NA)  
2. CLA-pretreated non activated (NA+CLA) 
3. Thrombin receptor activating peptide (TRAP)-activated sample (TRAP) 
4. CLA-pretreated TRAP-activated (TRAP+CLA).  
In preliminary experiments 50 nM CLA was found to inhibit degranulation of platelets as well 
as PAC-1 binding without being toxic to cells so this concentration of CLA was applied in the 
experiments. TRAP (Sigma-Aldrich, St. Louis, MO) was used at a final concentration of 20 
µM.  
 
Isolation of normal human monocytes  
Hundred sixty mL of EDTA-anticoagulated (K2EDTA, Becton Dickinson vacutainer tube, San 
Jose, CA, USA) peripheral blood was drawn from healthy volunteers, and peripheral blood 
mononuclear cells (PBMC) were separated on Ficoll Histopaque 1077 (Sigma-Aldrich, St. 
Louis, MO, USA). Normal human monocytes were isolated from PBMC by a magnetic 
monocyte separation, negative isolation kit (Dynabeads® Untouched Human Monocytes, 
Invitrogen by Life Technologies) using beads in combination with an antibody mix (contains 
biotinylated mouse IgG antibodies for CD3, CD7, CD16 (specific for CD16a and CD16b), 
CD19, CD56, CDw123 and CD235a - Glycophorin A -) to remove all unwanted cells from the 
sample, leaving only the monocytes behind. This technique – unlike other column based 
methods – provides a 95% viability that is important from the point of view of functional tests 
like thrombin generation. The cell count was adjusted to 5 x 106/mL in phosphate-buffered 
saline (PBS) for thrombin generation measurements and 107/mL for flow cytometric analysis. 
Normal human monocytes were used as negative control in our leukemic cell experiments. 
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Cell cultures and culturing 
The THP-1 cell line was a gift of prof. Dr. György Vereb (Department of Biophysics and Cell 
Biology, University of Debrecen, Hungary). MOLM-13 and MV4-11 cell lines were purchased 
from German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, 
Germany). Based on the WHO 2008 criteria for the stratification of AML, all these cell lines 
belong to the unfavorable prognostic group with multiple chromosomal abnormalities. As a 
positive control an acute promyelocytic leukemia cell line (NB4, which was a gift of prof. Dr. 
Zoltán Balajthy, Department of Biochemistry and Molecular Biology, University of Debrecen, 
Hungary) was used. All cell lines were maintained in suspension cultures, in RPMI-1640 
medium (Sigma-Aldrich, St. Louis, MO), supplemented with 15% fetal bovine serum (heat 
inactivated, Sigma-Aldrich, St. Louis, MO) were grown in a cell incubator at 37ºC in a 
humidified atmosphere of 5% CO2 in air. The duplication times of monocytic leukemia cells 
were 35-48 hours which was investigated by cell counting at 48 hours and cell cycle analysis 
at 0, 24 and 48 hours. The medium was changed three times a week, when maximum cell 
density was set to 0.5 x 106/mL in case of monocytic leukemia cell lines and to 0.3 x 106/mL 
in case of the NB4 cell line. Cell cultures were subcultured by total medium replacement by 
using centrifugation every seven days. Cell viability was >90%, evaluated by trypan blue 
exclusion before each experiment. Upon centrifugation (190 g, 25°C, 10 minutes) the leukemic 
cells were resuspended in PBS at a concentration of 5 x 106/mL for the functional thrombin 
generation test and to 107/mL for flow cytometric analysis. 
 
Leukemic cell immunophenotype characterization by flow cytometry 
For immunophenotyping surface staining of cells were carried out according to standard 8-color 
procedures. Fifty microliters of cell suspension adjusted to cell count of 10x109/L by PBS was 
incubated by saturating concentrations of directly conjugated antibodies for 15 minutes at room 
temperature in the dark with antibodies against different cell surface and cytoplasmic epitopes. 
Labelling was carried out with CD14-FITC, CD11b-PE, HLA-DR-PerCPCy5.5, CD4-PB, 
CD15-FITC, CD34-PerCPCy5.5, CD71-FITC, CD117-PE, CD38-APCH7 (Becton Dickinson 
Biosciences, San José, CA), CD34-APC, CD13-PECy7, CD64-APCAF750, CD33-PECy5.5, 
CD56-PECy7 (Beckman Coulter, Marseille, France), CD45-PO (Invitrogen, Thermo Scientific 
Inc., Walthman, MA), MPO-PE (Dako Cytomation, Glostrup, Denmark), and FXIII-A-FITC. 
PFA-fixed samples were kept at 4°C for maximum 24 h. Flow cytometric measurements were 
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carried out on a FACSCanto II (Becton Dickinson Biosciences, San Jose, CA) flow cytometer 
using the same setting for all investigated samples. Data obtained on 50 000 cells were acquired 
and stored in list-mode data files. Data were analyzed by FACSDiva software (Becton 
Dickinson Biosciences, San José, CA). 
 
Determination of thrombocyte surface phosphatidylserine expression by 
flow cytometry 
Platelet rich plasma (PRP, 110 µL) - using 250 G/L thrombocyte count - was pre-incubated 
with either HEPES buffer (15 mM NaCl, 25 mM HEPES, pH 7.4) containing 0.5% 
dimetilsulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO) as control or the protein phosphatase 
inhibitor CLA, for 30 minutes at 37ºC in a water bath. CLA was used at a final concentration 
of 50 nM. After pre-incubation, platelets were activated either by TRAP at a final concentration 
of 20 µM or by thiomersal at a final concentration of 200 µM for 15 minutes at 37ºC in a water 
bath. Then PRP (5 µL) was stained with 5 µL monoclonal CD41-PE antibody, 5 µL Annexin-
V-FITC and Annexin V binding buffer (1x concentrate) was added to examine the PS-
expression of the platelets. In each experiment 10 000 events were collected in the platelet gate, 
measured by an FC500 flow cytometer and results were analysed with the Kaluza software 
(Beckman Coulter, CA). 
 
 
Determination of phosphatidylserine and tissue factor expression of 
leukemic cell lines by flow cytometry 
For the analysis of PS-exposure of monocytes and cell lines we used FITC-labelled Annexin V 
and Annexin V Binding Buffer from Becton Dickinson Biosciences, San José, CA. Tissue 
factor expression was detected by a monoclonal PE-conjugated anti-TF antibody (R&D 
Systems, Minneapolis, MN). 100 µL isolated monocytes or leukemic cells (1 x 106 cell/100 
µL) were stained with10 µL TF-PE and 5 µL Annexin-V-FITC antibody for 30 minutes, at 
room temperature in dark. Then they were washed twice with PBS and cells were resuspended 
in 500 µL Annexin V Binding Buffer. In each experiment 30000 events were collected by an 
FC500 flow cytometer and results were analysed with the Kaluza software (Beckman Coulter, 
Miami, FL). 
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Microparticle separation and microparticle number determination by flow 
cytometry 
First, 3.0 x 106 of cells were centrifuged at 190 g, 25°C for 10 minutes and the supernatant was 
discharged, cells were resuspended in fresh RPMI-1640 supplemented with 15% fetal bovine 
serum to adjust their cell count to 0.5 x 106/mL in case of monocytic leukemia cell lines and to 
0.3 x 106/mL in case of NB4 cell line. The cells in suspension were cultured for 48 hours and 
the cell count was set to 5 x 106/mL. Cells were removed from the suspension by centrifugation 
(190 g, 25°C for 10 minutes) followed by a brief removal of residual intact cells from the 
supernatant by spinning at 13 000 g for 2 minutes at room temperature (RT). Subsequently, 
microparticles were isolated by a high speed centrifugation (16 100 g, 30 minutes, RT), washed 
with PBS and centrifuged (16 100 g, 30 minutes, RT). MPs were resuspended in 1 mL PBS. 
Prior to MP measurements, counting calibration beads were used for cytometer settings. 
Megamix-Plus SSC (Biocytex, Marseille, France) was used for this purpose, which is a mix of 
fluorescent beads of variable diameter selected to cover a major part of the microparticle size 
range, using SSC as a size-related parameter. The flow cytometer has been calibrated by these 
Megamix beads and we found that by the suggested marker (SSC) the FacsCanto II (Becton 
Dickinson, San Jose, CA) was capable of detecting beads in the range of 0.16 – 1.0 µm. MP 
number was evaluated by PS-positivity as measured on the cytometer.  
 
Determination of procoagulant activity (PCA) of the leukemic cell lines  
In the PCA tests 100 µL of normal or factor VII (FVII) deficient (Siemens, Marburg, Germany) 
or factor XII (FXII) deficient plasma (Siemens, Marburg, Germany) was incubated with 100 
µL of PBS, monocytes or leukemic cells at 37°C for 3 minutes. Leukemic cell procoagulant 
activity was also measured after blocking the surface TF with a human anti-tissue factor 
antibody. Leukemic cell were incubated with a goat polyclonal IgG anti human-antibody (final 
concentration of 25 µg/mL, R&D Systems, Minneapolis, MN) for 15 minutes. 100 µL of 
blocked leukemic cells was incubated with 100 µL of normal plasma at 37°C for 3 minutes. As 
a negative control for the blocked sample we used goat serum at a final concentration of 45 
µg/mL (Sigma-Aldrich, St. Louis, MO). Than 100 µL of 20 mM CaCl2 was added to initiate 
clotting. Fibrin formation in seconds was measured by a KC-1 mechanical coagulometer. A 
1:10 dilution of recombinant thromboplastin (Dade Innovin, Siemens, Marburg, Germany) was 
arbitrarily taken as 12 800 mU and a serial dilution was used to generate the thromboplastin 
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calibration curve on a double logarithmic scale. The clotting times were converted to 
procoagulant activity expressed as mU/105 cells.  
 
Clot retraction analysis 
PRP (720 µL) was preincubated with buffer control or CLA, then activated by TRAP. In a glass 
tube, 800 µL of each four samples were incubated with CaCl2 (at a final concentration of 25 
mM) for 60 minutes at 37ºC in a water bath. At time points 0, 20, 40 and 60 minutes, photos 
were taken to document clot formation. At the end of the experiment, the volume of the extruded 
serum was determined by an analytical balance. The amount of fibrin monomer in the extruded 
serum was measured by a latex enhanced quantitative immunoassay (Stago, Asniére, France) 
on the ACL-TOP coagulation analyser (Instrumentation Laboratory, Bedford, MA). 
 
Procoagulant effect of leukemic cells and their microparticles determined 
by thrombin generation test 
Thrombin generation test (TGT) was performed as described previously using the 
Thrombinoscope CAT (Calibrated Automated Thrombogram, Maastricht, The Netherlands) 
assay according to the manufacturer’s instructions (Diagnostica Stago, Asnières, France). 
Briefly, 80 microliters of normal plasma/VII-deficient plasma/XI-deficient plasma/XII-
deficient plasma was incubated with 20 µL of monocyte or leukemic cell for 10 minutes in 
round-bottomed 96-well black microplates in 37°C. In microparticle measurements 80 
microliters of normal plasma was incubated with 20 µL of microparticles. For each sample, a 
calibrator (Thrombin CalibratorTM) was run in parallel in order to correct the fluorescence signal 
for substrate consumption and plasma color variability. Thrombin generation was initiated by 
the addition of 20 µL of FluCa-KitTM (a mixture of Fluorogenic substrate and Fluo-Buffer 
containing CaCl2). All samples were run in duplicates. Fluorescence was detected by a 
Fluoroskan Ascent® fluorimeter (Thermo Fischer Scientific, Waltham, MA) and the thrombin 
generation curves were analysed by the Thrombinoscope software (Thrombinoscope BV, 
Maastricht, The Netherlands). Thrombin generation curves were characterised by the following 
parameters (calculated and presented by the Thrombinoscope software):  
1. lagtime: the moment at which thrombin generation starts 
2. endogenous Thrombin Potential (ETP): the area under the curve 
3. peak Thrombin: the highest thrombin concentration 
4. time to Peak: the time until the Peak Thrombin 
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5. start Tail: the time to end-point of thrombin generation 
6. velocity Index: the slope of the curve between the beginning of thrombin generation and 
the Time to Peak parameter. 
 
Determination of platelet function modulation and CLA effect on thrombin 
generation 
Eighty microliters of pretreated PRP was incubated with 20 µL of standard preparations of 1 
pM recombinant tissue factor (rTF, PRP-Reagent, Thrombinoscope BV, Maastricht, The 
Netherlands) for 10 minutes in round-bottomed 96-well black microplates. Thrombin 
generation was initiated by the addition of 20 µL of a mixture of fluorogenic substrate and Fluo-
Buffer that contained CaCl2 (Thrombinoscope BV, Maastricht, The Netherlands). Fluorescence 
was detected by a Fluoroskan Ascent® fluorimeter (Helsinki, Finland) and the thrombin 
generation curves were analysed by the Thrombinoscope software (Thrombinoscope BV, 
Maastricht, The Netherlands). 
 
High-speed confocal measurement of platelet cytosolic Ca2+ levels 
For measurements of intracellular Ca2+ levels, PRP was prepared as described above and RGDS 
peptide was added to prevent aggregation. PRP (100 µL) was loaded with 1.5 µL of 2 mM 
Fluo-4-AM for 10 minutes at 37ºC in a water bath. The cells were co-loaded with Fura-Red by 
addition of 2 µL of 1 mM Fura-Red-AM for 30 minutes at 37ºC in a water bath. Before 
centrifugation, 2 mL of HEPES-buffered saline was added and after centrifugation at 350 x g 
for 20 minutes at RT, the co-loaded platelets were collected and resuspended in 100 µL of the 
same buffer. 
Platelets loaded with the calcium-indicator dyes were imaged using a Zeiss LSM 5 LIVE (Carl 
Zeiss AG, Jena, Germany) high-speed confocal scanning unit with a 40x oil immersion 
objective (NA: 1.3). The final 100 µL solution was pipetted onto a glass coverslip secured 
above the objective within a temperature-controlled chamber and was allowed to rest for 2 
minutes before the measurement. Both the chamber and the objective had been preheated to 37 
ºC and this temperature was kept constant during the measurement. Frames (x-y images) were 
recorded at a rate of 5 Hz for 5 minutes using 488 nm excitation wavelength and two detection 
channels: a band pass filtered channel between 500 and 525 nm for the Fluo-4 signal and a long 
pass filtered channel above 635 nm for the Fura-Red signal. The wide gap between the cutoff 
wavelengths ensured that there was minimal crosstalk between the channels. TRAP was added 
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by pipetting 4 µL of 500 µM TRAP solution to the platelet suspension on the coverslip. 
Measurement was continuous during the addition of TRAP. The confocal microscopic 
measurement and the evaluation of fluorescence signals were performed by János Vincze, MD 
from the Department of Department of Physiology, University of Debrecen. 
 
Statistical analysis 
The statistical analysis was performed with GraphPad Prism 5.0 version. Normality of the data 
was evaluated by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Elements outside mean ± 
2SD were removed as outliers. Data are expressed as mean ± SD or mean ± SEM. 
Predetermined pair-wise differences were analysed by paired t test and in case of a non-normal 
distribution, the Wilcoxon matched paired test was used. For non pairwise comparison, 
unpaired t test (Gaussian distribution) and Mann-Whitney test (non Gaussian) were used. 
ANOVA with Bonferroni post test (Gaussian distribution) or Kruskal-Wallis test with Dunn’s 
post test (non Gaussian distribution) were used for multiple group comparison. P values less 
than 0.05 were considered as statistically significant. 
 
 
 
RESULTS 
 
The effect of TRAP and thiomersal activation and CLA inhibition on the 
surface PS-expression and microparticle formation of platelets 
In a series of experiments, we determined the level of PS-exposure to analyse the effects of 
CLA on resting and activated platelets. PRP samples were preincubated with HEPES buffer 
(control) containing 0.5% DMSO or 50 nM CLA in DMSO for 30 minutes. Platelets were 
identified according to their CD41-PE staining then PS-expression was determined by 
Annexin-V positivity. The PS-expression of non-activated (NA) samples was low (mean ± 
SD=3.03 ± 0.84) and it was further decreased by CLA pretreatment (mean ± SD=1.75 ± 0.67, 
p=0.004). The PAR-1 receptor agonist, TRAP significantly increased the number of platelets 
expressing PS (mean ± SD=18.7 ± 3.23) compared to the NA sample (p<0.0001) while CLA 
pretreatment completely prevented PS upregulation in TRAP-stimulated platelets (p<0.0001). 
Contrary to the TRAP activation, thiomersal activation induced 96% PS-expression that could 
not be prevented by CLA-preincubation. CLA-pretreatment completely decreased the number 
of microparticle events in NA and TRAP-activated samples.  
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The effect of CLA on clot retraction 
It could be observed that clot formation and retraction commenced already by 20 minutes and 
by 60 minutes both the non-activated and the TRAP activated samples displayed an intense clot 
retraction. The CLA-pretreated samples however were much less retracted. In accordance with 
this morphology the CLA pretreated samples showed a tendency for extruding less serum (NA: 
754.4 mg vs. NA + CLA: 653.2 mg, p=0.0085). The fibrinogen concentration was 
unmeasurably low in the samples by 60 minutes, nevertheless the fibrin monomers (FM) were 
determined by a quantitative assay and it was found that in the extruded sera of CLA-pretreated 
samples more FM was detectable compared to non-pretreated samples.  
 
Thrombin generation of platelet rich plasma samples after modulation 
The thrombin formation was faster, the lagtime (NA: mean ± SD: 8.1 ± 1.1 min; TRAP: mean 
± SD: 6.5 ± 1.5 min) and time to peak (NA: mean ± SD: 18.2 ± 2.8 min; TRAP: mean ± SD: 
11.9 ± 1.5 min) were shorter in case of TRAP activation compared to the non-activated sample. 
TRAP activation increased the peak thrombin and also the velocity index. CLA preincubation 
significantly prolonged the time of thrombin generation in TRAP activated samples, but did not 
have significant effect on the NA sample. CLA attenuated the peak thrombin and velocity index 
already in NA samples and completely blocked the TRAP-elicited augmentation in these 
parameters. 
 
The effect of CLA inhibition and TRAP activation on the intracellular Ca2+ 
level 
First, all NA and CLA-pretreated platelets were observed for at least 60 seconds, than TRAP 
was added to the sample. Platelet intracellular Ca2+ levels were measured after activation of 
non-activated or CLA pretreated sample. Two typical patterns of intracellular calcium 
concentration changes of platelets were observed on TRAP-activated samples without CLA 
pretreatment: no transient change after the addition of 20 µM TRAP or a transient increase in 
the Ca2+ level. In the case of samples that were not pretreated, 22.2 % of platelets showed 
transient cytosolic Ca2+ increase upon TRAP addition. In case of platelets preincubated with 
calyculin-A, none of the investigated 122 cells showed calcium transients after TRAP 
administration during the time course of the measurement providing evidence for CLA 
blockage of Ca2+ elevation 
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Thiomersal evoked a prolonged elevation of cytosolic calcium in all the platelets followed by 
sustained store-operated calcium entry. Thiomersal induced cytosolic calcium elevation could 
not be blocked by CLA.  
 
Immunophenotype and genetic characteristics of leukemic cell lines 
THP-1 is a monocytic leukemia cell line derived from a patient at relapse, MOLM-13 is a 
secondary monocytic leukemia developed from myelodysplasia RAEB and MV4-11 is a de 
novo monocytic leukemia cell line. The myeloid marker CD33 was the only antigen that was 
uniformly expressed on the surface of all cell lines, while the other pan-myeloid marker CD13 
as well as various monocytic markers displayed a variable expression. The three cell lines 
showed different immunophenotype with incongruent expression of monocytic and myeloid 
markers, however, THP-1 seemed to be the most mature with no CD34 and small CD117 
expression. Complex cytogenetic abnormalities are present in all cell lines that are responsible 
for their poor prognosis, irrespectively of the FLT3-ITD mutation status. 
 
Phosphatidylserine (PS) and tissue-factor (TF) expression of normal 
monocytes and leukemic cell lines 
In case of non-activated normal human monocytes the TF-expression was high (mean ± SD: 
73.4 ± 20.3%), while the TF-expression was different in the cell lines. The TF-expression of 
THP-1 cell line (mean ± SD: 73.1 ± 11.6%) was not different compared to normal monocytes. 
MOLM-13 cell line showed the lowest TF positivity (mean ± SD: 3.9 ± 0.6%).  The TF-
expression of MOLM-13 and MV4-11 (mean ± SD: 21.2 ± 7.4%) cell lines were significantly 
lower compared to monocytes, THP-1 and NB4 cell lines (p<0.001). 
Among the three monocytic leukemia cell lines, the lowest PS-expression was observed on 
THP-1 cells (mean ± SD: 6.5 ± 2.3 %) and was somewhat higher on the MOLM-13 (mean ± 
SD: 12.1 ± 3.3 %) as well as on the MV4-11 cell line (mean ± SD: 21.8 ± 8.4 %)  although 
differences were non-significant. There was, however, a significant difference in the intensity 
of PS-expression as characterized by the ratio of mean fluorescence intensity (MFI) values of 
the PS positive population divided by the MFI value of the unlabeled cells. The mean ± SD of 
the MFI ratio from 5 experiments  was 14.12 ± 3.9 for THP-1 cells that was non significantly 
different from MV4-11 cells (mean ± SD: 20.23 ±12.12) but in case of MOLM-13 cells this 
ratio was significantly higher than in the other two cell lines (mean ± SD: 75.91 ± 30.22). This 
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means that although MV4-11 cells expressed the highest percentage of PS positivity, the 
intensity of expressed PS was highest on the MOLM-13 cell line. 
 
Determination of microparticle number  
By using the same cellular density for culturing during a 48-hour period all three cell lines 
generated considerable amount of MP. We isolated these MPs and investigated their 
procoagulant activity by TGT. We found that the THP-1 cell line produced twice as much MP 
as the other two cell lines. The mean MP number was 4.7x 107/5 x 106 cells vs. 2.2 and 2.6 x 
107/5 x 106 cells in the MOLM-13 and MV4-11 cell lines respectively. The MP number of the 
positive control NB4 cell line was between these values (3.3x 107/ 5 x 106 cells). There was no 
significant difference among the number of microparticles shed by the different cell lines. 
 
Procoagulant activity measured by a one-stage clotting assay (PCA) 
The clotting time of normal plasma containing PBS but no cells was over range (> 200 sec, data 
not shown) and similar values were observed using isolated normal human monocytes, both 
referring to a very low procoagulant activity. Using the same cell concentrations, all three cell 
lines displayed significantly shorter clotting times and consequently higher procoagulant 
activity. The neglectable PCA of isolated normal human monocytes was unaffected by FVII 
deficient plasma. We observed that the FVII deficient plasma and a polyclonal anti-human 
tissue factor (ahuTF) antibody pretreatment completely abolished the fibrin forming capacity 
of all monocytic leukemia cell lines resulting in very low procoagulant activity, while FXII 
deficient plasma had no significant blocking effect. Although, the procoagulant activity of the 
acute monocytic leukemia cell lines was significantly increased compared to the buffer control 
or monocytes, there was no significant difference between the three cell lines in normal plasma.  
 
Thrombin generation of leukemic cell lines 
Another way to evaluate the procoagulant activity of cells was done by the thrombin generation 
test. The positive control NB4 cell line resulted in an abrupt increase in thrombin and reached 
the highest Peak thrombin value. The monocytic leukemia cell lines (THP-1, MOLM-13 and 
MV4-11) displayed rather similar thrombin generation profiles and thrombin was formed much 
faster than in case of normal human monocytes.  
There was no significant difference between the thrombin generation of normal monocytes 
compared to PBS in normal plasma. Intact leukemic cells of all three cell lines significantly 
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shortened the lagtime and time to peak, the shortest times were observed in the positive control 
NB4 cells. FVII deficient plasma and anti-TF pretreatment completely eliminated the 
shortenings in the monocytic leukemia cells, while FXI and FXII deficient plasma had no such 
effect. In case of the Time to Peak parameter the TF-blocked and FVII deficient samples exerted 
the same effect on THP-1 cells, but attenuated neutralizing effects were observed on the two 
other cell lines. Importantly, on the MOLM-13 cell line and to a smaller extent in case of MV4-
11 cells, FXI deficiency also prolonged the Time to Peak similarly to TF blockage while FXII 
deficient plasma did not significantly affect this parameter. We found that healthy monocytes 
generated the same low amount of thrombin as normal plasma without any cells, while all 
monocytic leukemia cell lines induced considerable thrombin generation as observed in the 
Peak thrombin parameter, however, it did not reach the level of the promyelocytic leukemia 
NB4 cells. The elevation in the quantity of produced thrombin was non-significant in case of 
THP-1 cells compared to normal monocytes but peak thrombin values were significantly higher 
than the monocyte control in case of the MOLM-13 and MV4-11 cell lines. The peak thrombin 
parameter was dependent on factors VII, XI and XII in case of all cell lines, however, a 
nonsignificant FVII dependence was observed in case of MOLM-13 cells. Factor VII deficiency 
affected nearly all investigated parameters, while eliminating factor XI from the system caused 
a considerable reduction in thrombin generation that was particularly striking in case of 
MOLM-13 and MV4-11 cells. Interestingly, anti-TF pretreatment - with the antibody that 
effectively blocked the shortening of lagtime - was ineffective in modulating the formed 
thrombin quantity. 
 
Thrombin generation of microparticles  
By using the same cellular density for culturing during a 48-hour period all three cell lines 
generated considerable amount of MP. We isolated these MPs and investigated their 
procoagulant activity by TGT. These MP have strong thrombin inducing ability as 
demonstrated by the significantly reduced lagtime and time to peak values, compared to a buffer 
control (PBS). No significant differences were observed in peak thrombin and velocity index 
parameters. 
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DISCUSSION 
 
 
Possibilities of platelet function modulation 
Platelets have an essential role in the pathogenesis of arterial atherosclerotic diseases. For the 
investigation of modulation of platelets, we set up an in vitro ‘cellular’ model.  In our 
experiments we studied the platelet activation according to PS-expression, and investigated 
their effect on coagulation and thrombin generation with functional tests (clot retraction 
analysis, thrombin generation test). Furthermore, we examined the effect of the protein 
phosphatase inhibitor, CLA on platelet PS-expression, function and intracellular Ca2+ level.  
In our experiments instead of thrombin we utilized TRAP - a potent activator of PAR-1 on 
platelets - to avoid early clotting and any potential pleiotropic effects of thrombin.  
Serine/threonine protein phosphatases play an essential role in cells, including platelet 
signalling, metabolism, platelet secretion and initiation of aggregation. Under experimental 
conditions in phosphatase-inhibitor treated platelets, actin polymerization was inhibited, 
microtubules were reorganized in sustained pseudopods, and the phosphorylation of myosin 
light chain was not enhanced upon thrombin stimulation. The myosin phosphorylation is crucial 
in actomyosin contraction for platelet secretion and activation. 
Activation of platelets by various agonists is accompanied by a transient intracellular Ca2+ 
elevation, which is obligatory for the initiation and propagation of platelet responses such as 
adhesion, aggregation and degranulation. The rise in intracellular calcium is a result of the 
calcium release from the intracellular stores mediated by the IP3 receptor. In earlier studies, it 
was found that CLA treatment of activated platelets suppressed the activation induced rise in 
Ca2+ levels measured by fluorescence spectrophotometric techniques. We have investigated 
platelet cytosolic Ca2+ levels by a real-time ratiometric measurement with confocal microscopy, 
to more appropriately characterize changes in intracellular calcium signals. It was found that 
activating platelets by TRAP, causes a clear intracellular Ca2+ signal in 22.2% of platelets that 
was abolished by CLA-pretreatment and this effect was not due to affect the resting calcium 
levels.  
In control samples, upon TRAP activation (in non-CLA pretreated samples), a heterogeneous 
response was predictable there is current evidence for platelet subpopulations. These platelets 
were described as procoagulant platelets, while the remaining population of platelets can be 
considered as contracting platelets where the GPIIb/IIIa activation is observed. Heterogeneity 
of platelet responses and functions are important in the thrombus-forming process. After 
   
 20 
platelet activation, distinct platelet populations may have different roles in the coagulation 
process, depending on their activation state and surface properties. Similarly, to calcium 
signals, not all platelets express PS upon activation,  
In our experiments, we also observed that only 20% of platelets responded by PS-expression 
upon TRAP-stimulation a similar ratio observed in case of calcium transients. By using 
thiomersal, a direct activator of the intracellular IP3 receptors 96% of platelets showed PS-
positivity that could not blocked by CLA. We could verify both by flow cytometric PS-
expression studies, as well as by the ratiometric calcium measurement, that PP inhibition by 
CLA does not impair direct IP3 receptor stimulation, so its effect is exerted upstream of the IP3 
receptor.  
Raised Ca2+ levels lead to the exposure of PS on the platelet surface that serves as a site for the 
assembly of intrinsic and extrinsic tenase and prothrombinase complexes, thus it is critical for 
thrombin generation in PRP. The speed of thrombin generation and the activity of generated 
thrombin were shown to be the most useful parameters to evaluate the thrombin generation of 
PRP. CLA inhibited TRAP-elicited thrombin generation and we demonstrated that CLA also 
inhibited that platelet subpopulation which takes part in the clot retraction. 
Taken together, these findings indicate that inhibition of protein phosphatases by CLA-
pretreatment can be regarded as a useful tool to investigate the platelet subsets that contribute 
to enhanced thrombin formation and clot retraction. 
 
 
Enhanced procoagulant activity of acute monocytic leukemia cell lines 
In the initiation of coagulation, the key surface protein is TF that binds factor VIIa and rapidly 
leads to the activation of the extrinsic coagulation cascade, leads to thrombin generation and 
fibrin formation. According to previous concept TF is not present in the circulating blood, it 
can be found under the endothelial layer in the extravascular space. In earlier studies we have 
observed a considerable difference in tissue factor activity of activated intact and lysed 
monocytes, as the latter displayed a much higher procoagulant activity and similar differences 
between intact and lysed cells have been described more recently for PBMC samples derived 
from patients suffering from AML. Using lysed cancer cell lines, some authors found FVII-
dependence of the promyelocytic NB4 cell line and the MCF7 breast cancer cell line, but they 
detected very low thrombin generation, with no TF activity and no FVII-dependence in other 
leukemia cell lysate like the K562 chronic myeloid leukemia and the HEL cell erythro-leukemia 
cell lines. 
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According to novel experiments, in physiological conditions, the monocytes the only cells in 
the circulation that can synthetize TF and upon activation monocytes can express it - in a 
significant amount - on their surface, which could participate to coagulation. 
Isolated, non-activated monocytes used as negative control in our experiments, 73% of them 
expressed TF on their surface but no functional role was detected during the functional 
procoagulant activity and thrombin generation tests. The thrombin generation capacity of these 
monocytes was the same as the control sample without cells. It is known that TF can appear in 
two forms on the surface on vascular cells. It can be as a functionally inactive form, ‘cryptic’ 
or it can be active, ‘decryptic’.  
Our monocytic leukemia cell lines showed different TF expression, but there was no significant 
difference between the procoagulant effect of the acute monocytic leukemia cell lines in normal 
plasma, measured by functional tests. 
According to recent results, different ways can lead to TF activation. The majority of the 
evidence in the literature point out that exposure of anionic phospholipids, such as PS, on the 
outer leaflet of plasma membrane is a key regulator of TF procoagulant activity at the cell 
surface. There was no significant difference found between the PS-expression of our acute 
monocytic leukemia cell lines, but the intensity of PS-expression in case of the MOLM-13 cell 
line was significantly more intense than the intensity of the THP-1 and MV4-11 cell lines. 
Leukemic cells displayed significantly higher procoagulant activity compared to normal 
monocytes. We supposed that various pathways are involved differently in this process, 
therefore we investigated the role of FXII and FVII that are essential in the initiation of the 
intrinsic and extrinsic coagulation pathway.   In a one-stage clotting assay very little thrombin 
is sufficient to form a clot in the coagulometer within a few minutes as a result of the formed 
fibrin mesh. This process seems to be totally FVII-dependent as was exemplified by the parallel 
abrogating effect of VII-deficient plasma and tissue factor blocking antibody.  
In the thrombin generation assay, however the reaction is followed up to 1 hour, well beyond 
that of fibrin formation, enabling one to better characterize the contribution of individual 
coagulation factors by using factor deficient plasmas. Based on our observations we propose 
that FVII is important in triggering the procoagulant effect evidenced by the fibrin formation 
and lagtime in the TGT. Subsequent thrombin generation as determined by the time to peak and 
peak thrombin, however, is very much dependent on factor XI and partially on FXII as these 
proteases seem to be necessary in the propagation of the coagulant reaction. The particular role 
of FXI in peak thrombin for the MOLM-13 and to some degree the MV4-11 cells suggest that 
the thrombin generation is mediated by a feedback activation of FXI by thrombin at least 
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partially independently of FVII and FXII. This is in agreement with the role of FXI in affecting 
the time to peak by MOLM-13 and partially for MV4-11 cells. The discrepancy between the 
effect of using FVII deficient plasma or anti-TF antibody in peak thrombin measurement for 
THP-1, MOLM-13 and MV4-11 cells might stem from a TF-independent activation of FX/FIX 
by FVII and PS exposed on the cells and a resultant feedback activation of FXII by thrombin.  
It was described that in several disorders microparticles shed by endothelial cell or blood cells 
display a procoagulat effect and that this can influence intravascular coagulation. We supposed 
that microparticles from our leukemic cell lines have an enhanced procoagulant effect. We have 
found that an intact cell produces 4-10 microparticles in a 48-hour period. 
The overall contribution to the generated thrombin depends on the surface of the particle and 
its potentially procoagulant receptors. If we consider leukemic monocytes and their 
microparticles as spheres, their surface can be calculated. Taking into consideration the 
detection limit of the Canto-II flow cytometer that was used for the analysis of microvesicles 
and monocytic cells we can estimate the radii of the MP and cells at 0.3 µm and 10 µm 
respectively. Based on the formula for the calculation of the surface for spheres (A = 4 r2 π) the 
intact cells possess about a 1000-fold larger surface than that of the microparticles. Since during 
a 2-day culturing, 4-10 microparticles were released from one intact leukemic cell, this would 
imply that per a given surface, MP derived from these monocytic leukemia cells are roughly a 
100-fold more procoagulant than their parent cells. All MP contribute to thrombin generation 
mostly by reducing the lagtime and to a much lesser extent the time to peak parameters. This 
means that MP derived from these monocytic cell lines rather affect the initiation- and not the 
propagation phase - of thrombin formation.  
In these experiments we have found, that monocytic leukemia cell lines and MP generated by 
these cells exhibit significantly higher procoagulant activity compared to normal monocytes 
and that this effect is primarily TF dependent, however, other factors may modulate this effect. 
Our results demonstrate that functional assays may provide a useful tool to identify cell induced 
thrombin generation in acute myeloid leukemias.  
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SUMMARY 
We studied the effects of the protein phosphatase inhibitor, Calyculin-A on platelet activation, 
clot formation and thrombin generation. We found that CLA completely blocked the PS-
expression of platelets in both the non-activated and the TRAP-activated platelet rich plasma 
sample. CLA also inhibited the process of thrombin generation. Non-activated and TRAP-
activated samples displayed an intense clot retraction by 60 minutes, while CLA-pretreated 
samples were much less retracted. 
CLA effectively inhibits phosphatases in resting and activated platelets and can be used in a 
wide variety of platelet functional assays ranging from clot retraction, via calcium 
measurements, to thrombin generation. With the simultaneous use of selective platelet 
activators it can be utilized to dissect biochemical pathways during thrombus formation.  
We investigated three monocytic leukemia cell lines, derived from a patient with de novo AML, 
a case of relapsed AML and from an AML case that developed secondary to myelodysplastic 
syndrome. We hypothesized that monocytic leukemic cells have a higher procoagulant activity 
thus, we characterized their thrombin generating potential by different assays using coagulation 
factor-deficient plasmas and TF neutralization. Results were compared to isolated normal 
human monocytes as negative- and to an acute promyelocytic leukemia cell line as positive 
controls. Because in previous studies microparticles from various cells have been shown to 
differentially modulate clot formation, we also tested the thrombin generating potential of the 
MPs derived from these leukemic cell lines.  
In these experiments, we have found that monocytic leukemia cell lines and MP generated by 
these cells exhibit significantly higher PCA compared to normal monocytes and that this effect 
is primarily TF dependent; however, other factors may modulate this effect. Our results 
demonstrate that functional assays may provide a useful tool to identify cell induced thrombin 
generation in acute myeloid leukemias.  
 
 
 
MAIN SCIENTIFIC RESULTS, OBSERVATIONS 
1. After TRAP activation 25% of platelets showed PS- expression and cytosolic calcium 
transients during platelet function analysis. 
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2. TRAP activation in platelet rich plasma elicited faster thrombin generation and higher peak 
thrombin compared to non-activated sample. 
 
3. The protein phosphatase inhibitor, CLA completely blocked the TRAP-induced PS-
expression and thrombin generation in platelet rich plasma. 
 
4. In CLA-pretreated samples clot retraction could not be observed. 
 
5. By direct activation of intracellular IP3 receptors CLA could not blocked platelet activation. 
PP inhibition by CLA does not impair direct IP3 receptor stimulation, so its effect is exerted 
upstream of the IP3 receptor. 
 
6. Acute monocytic leukemia cell lines have a significant procoagulant effect, that is primarily 
TF-dependent, FVII has an important role in it, while the propagation of thrombin 
generation is FXI dependent to a smaller extent FXII dependent. 
 
7. Acute monocytic leukemia cell lines produce 4-10 microparticles in a 48-hour period and 
these microparticles are 100-fold more procoagulant than their parent cells. 
 
8. The thrombin generation test that was set to examine the cell lines can be suitable to 
investigate the thrombin generation in clinical cases of acute myeloid leukemia. 
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